A resident company of Sid Martin Biotech Institute at the University of Florida, Medosome Biotec is pioneering genetic-based solutions in childhood diseases.

ALACHUA, FLORIDA, US, January 9, 2017 /EINPresswire.com/ -- -- Medosome Biotec, LLC, a biotechnology company focused on genetically-based personalized medicine, has received accreditation for its genetic testing laboratory from the College of American Pathologists. Considered the global “gold standard” in laboratory accreditation, CAP-accredited laboratories must adhere to rigorous regulatory requirements in safety, accuracy and consistency. CAP accreditation qualified Medosome Biotec (MBT) to receive a license from the Agency for Health Care Administration to operate a Clinical Laboratory in Florida, and a CLIA Certificate of Accreditation from the Centers for Medicine and Medicaid Services.

Medosome Biotec is developing a program for personalized medicine which involves genetic testing of patients for pharmaceutical drug compatibility and tolerance. One of its products for treating a rare pediatric metabolism disorder is entering a FDA Phase III clinical trial. The company’s proprietary genetic test will provide physicians with accurate dosing information so that children may be treated without harmful side effects from this potential life-saving drug.

Richard Wagner, CEO of Medosome Biotec, stated, “Acquiring accreditation from CAP is a significant milestone for us. It is recognition for our commitment to providing the highest quality genetic testing and supports our mission to develop and commercialize genetic-based innovations in pediatrics.”

Mark S. Long, Director of Sid Martin Biotechnology Institute, said, “Medosome Biotec is an excellent example of the entrepreneur-researcher’s business model that thrives here at the Institute. MBT’s portfolio of technologies will advance the field of personalized medicine.”

The Institute offers startups collaborative, open laboratory workspace combined with financial, technical and human resources to nurture startups’ growth and success.

About Medosome Biotec, LLC

Medosome Biotec, LLC (MBT) is developing and commercializing technologies that enrich the lives of children by providing genetic-based solutions to childhood diseases, disabilities and deficiencies. MBT works in collaboration with the Department of Pediatrics and Department of Medicine in the College of Medicine at the University of Florida to expedite the commercialization of the technologies created in these departments. For more information, please visit www.mdbiotec.com.

About the Sid Martin Biotechnology Institute at the University of Florida

The Sid Martin Biotechnology Institute is the leading biotechnology incubator headquartered at the University of Florida in Alachua, Florida at Progress Park. The Institute has been honored with national and international awards for incubator excellence and achievements in technology commercialization, funding access, job creation and technology-based economic development. It is dedicated to mentoring and accelerating the growth of innovative early-stage bioscience and biotechnology companies, and supporting the economic growth of the North Central Florida region. For more information, visit www.sidmartinbio.org.

Merrie Shaw, Assistant Director
UF/Sid Martin Biotechnology Institute
386-462-0880
email us here